Increase in Adoption of Combination Therapy Expected to Drive Global Polycystic Ovarian Syndrome Treatment Market: Ken Research

The polycystic ovarian syndrome (PCOS) treatment market comprises of sale of services & related products that are used in drug stores, hospital pharmacies, and retail pharmacies to treat PCOS. PCOS is a hormonal disorder, which is a very common health problem caused by an imbalance of reproductive hormones. With PCOS, women have metabolism problems that affect their overall health & appearance. PCOS can cause missed/irregular menstrual periods and an irregular periods can lead to infertility & development of cysts or small fluid-filled sacs in the ovaries.

According to study, “Polycystic Ovarian Syndrome Treatment Market Global Report 2020-30” the key companies operating in the global polycystic ovarian syndrome treatment market are Pfizer, Inc., Merck KGaA, Sanofi, AstraZeneca, Ferring Pharmaceuticals, Inc., Bristol-Myer Squibb Company, Bayer AG, Novartis AG, Abbott, Addex Therapeutics Ltd, BIOCAD, Teva Pharmaceutical Industries Limited, Allergan plc., Johnson and Johnson, Ferring BV. These leading companies are increasingly investing for the initiatives to boost the awareness levels among the women about the feminine hygiene in the developing regions such as Middle East & Africa and Asia-Pacific.

Based on drug class, polycystic ovarian syndrome treatment market is segmented as oral contraceptive, insulin sensitizing agent, anti-obesity drugs, antiandrogens, and others. The insulin sensitizing agent segment holds major share in global market owing to rise in adoption of insulin sensitizing agents as the first line treatment for management of PCOS. Based on surgery, market is segmented as laparoscopic drilling and wedge resection. In addition, based on distribution channel, market is segmented as drug stores & retail pharmacies, hospitals pharmacies and online providers. The online providers segment is estimated to witness higher growth rate due to increase in awareness of online providers, rise in preference for online purchasing of drugs over the traditional methods and increase in number of internet users during the forecast period.

The polycystic ovarian syndrome treatment market is driven by increase in prevalence of PCOS, followed by easy accessibility to PCOS therapeutics, rise in awareness among patient population, rise in demand for PCOS medications, increase in adoption of combination therapy, and growth in technological advancements for detection of PCOS influence the market growth. However, lack of specific treatment for PCOS disorder, lack of approved therapeutics and unknown etiology & pathophysiology of PCOS may impact the market. Moreover, increase in number of unmet needs for treatment of PCOS is a key opportunity for market.

Based on geography, the North-American region dominates the global polycystic ovarian syndrome treatment market owing to increase in awareness and growth in availability of advanced healthcare facilities in the region. The European and Asian-Pacific regions are expected to grow at the highest growth rate due to increase in government initiatives for raising awareness about the symptoms & diagnosis of PCOS and available treatment are rising the number of women being diagnosed with this syndrome during the forecast period. The global PCOS treatment market was valued at US $3.83 billion in 2019 and it is expected to grow at a higher CAGR of 5.00% and reach US $4.65 billion by 2023.

For More Information, Click on the Link Below:-
https://www.kenresearch.com/healthcare/general-healthcare/polycystic-ovarian-syndrome/342054-91.html

Related Reports:-
https://www.kenresearch.com/healthcare/pharmaceuticals/polycystic-ovarian-syndrome/341128-91.html

Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Ken Research Pvt. Ltd.,
Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49 Gurgaon, Haryana - 122001, India

Ken Research is a Global aggregator and publisher of Market intelligence, equity and economy reports. Ken Research provides business intelligence and operational advisory in 300+ verticals underscoring disruptive technologies, emerging business models with precedent analysis and success case studies. Serving over 70% of fortune 500 companies globally, some of top consulting companies and Market leaders seek Ken Research’s intelligence to identify new revenue streams, customer/ vendor paradigm and pain points and due diligence on competition.

This release was published on openPR.